Log In
Print
BCIQ
Print
Print this Print this
 

Lonsurf, trifluridine/tipiracil (TAS-102)

  Manage Alerts
Collapse Summary General Information
Company Taiho Pharmaceutical Co. Ltd.
DescriptionOral combination of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil hydrochloride (TPI), an inhibitor of the FTD-degrading enzyme thymidine phosphorylase
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationColorectal cancer
Indication DetailsTreat refractory metastatic colorectal cancer (mCRC); Treat unresectable advanced or recurrent colorectal cancer refractory to standard therapies
Regulatory Designation

Japan - Standard Review (Treat refractory metastatic colorectal cancer (mCRC))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today